Aletia Farmer, MD
Internal Medicine · Lexington, KYNPI 1730353590
Payments from drug & device makers
Across 168 payments — averaging $17.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$573
- Lilly USA, LLC$340
- GSK$317
- Merck$137
- Takeda Pharmaceuticals U.S.A., Inc.$129
- Pfizer$114
- plus $1K from 29 others
What the payments were for
- Food & beverage$2,84598%
- Education$120%
- Other$452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $573 |
| Lilly USA, LLC | 21 | $340 |
| GSK | 23 | $317 |
| Merck | 8 | $137 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $129 |
| Pfizer | 7 | $114 |
| Novo Nordisk | 7 | $112 |
| Abbott | 6 | $101 |
| Gilead | 6 | $98 |
| Astellas Pharma US Inc | 5 | $82 |
| Axsome Therapeutics, Inc. | 3 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $73 |
| Exact Sciences | 4 | $62 |
| Dexcom, Inc. | 2 | $60 |
| Bayer | 4 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $53 |
| Boehringer Ingelheim | 2 | $45 |
| Welch Allyn | 1 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Pulmonx Corporation | 1 | $35 |
| Novartis | 2 | $30 |
| Xeris Pharmaceuticals, Inc. | 2 | $28 |
| AstraZeneca | 2 | $27 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| Seqirus USA Inc | 1 | $26 |
| Nevro Corp. | 1 | $26 |
| Medtronic | 1 | $24 |
| Shield Therapeutics Inc | 1 | $22 |
| Almatica Pharma LLC | 1 | $21 |
| Agios Pharmaceuticals, Inc. | 1 | $21 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Johnson & Johnson | 1 | $12 |
How this compares
$2,902 in reported general payments places this provider in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 124 | $126,818 |
| TrulicityDulaglutide | 95 | $113,765 |
| MounjaroTirzepatide | 103 | $106,112 |
| JardianceEmpagliflozin | 54 | $63,967 |
| EliquisApixaban | 42 | $51,430 |
| RybelsusSemaglutide | 23 | $38,517 |
| JanuviaSitagliptin Phosphate | 34 | $34,548 |
| XareltoRivaroxaban | 29 | $32,932 |
| LinzessLinaclotide | 30 | $22,646 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $21,008 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $15,701 |
| Tresiba Flextouch U-100Insulin Degludec | 21 | $15,435 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $10,774 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 94 | $10,371 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $8,814 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $340 | $219,876198 claims |
| Novo NordiskOzempic, Rybelsus | $112 | $165,335147 claims |
| Boehringer IngelheimJardiance, Tradjenta | $45 | $71,63867 claims |
| PfizerEliquis, Abrysvo, Premarin | $114 | $62,49679 claims |
| MerckJanuvia, Janumet Xr | $137 | $50,24946 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arexvy | $317 | $43,81699 claims |
| Johnson & JohnsonXarelto | $12 | $32,93229 claims |
| AbbVieLinzess, Synthroid | $573 | $25,12485 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $129 | $4,51115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,284 internal medicine providers in Kentucky.
Other internal medicine in Lexington
- Neil FarrisLexington$3M
- David ManninoLexington$168K
- John BordersLexington$166K
- Fadi BachaLexington$31K
- James BordersLexington$31K
- Jad BalloutLexington$30K
- Thomas von UnrugLexington$22K
- Danilo CoralesLexington$17K
- Mohamed TashaniLexington$17K
- Kelli TrentLexington$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.